Genentech / Roche could play this very strategically, if they like the look of what they have found under the initial agreement. They have always been the best fit for PYC, especially now that the focus has turned to oncology plus this is the second deal the two have had over the last 5 years. Roche / Genentech have always been right at the top when it comes to both cancer research and oncology revenue amongst big pharma & biotech. They still have up to 6 months left to decide what to do with the current $147M deal on drug delivery and presumably pseudomonas aeruginosa. Given their standing & interest in the oncology space PYC's data pack might be enough to encourage them to wrap it all up - can PYC put enough up before Genentech need to decide end of year ?
PYC Price at posting:
1.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)